The effects of cabergoline in reducing the size of endometrioma

The effects of cabergoline in reducing the size of endometrioma endometriosis

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150817023666N9

Enrollment

Registered

2018-01-30

Start date

2018-01-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis of ovary. Endometriosis of ovary

Interventions

Intervention 1: Intervention group: Patients receiving cabergoline. Intervention 2: Control group: Placebo recipient.

Treatment - Drugs

Placebo

Intervention group: Patients receiving cabergoline

Control group: Placebo recipient

Eligibility

Sex/Gender

Female

Age

No minimum to 45 Years

Inclusion criteria

Inclusion criteria: one-sided endometrioma Size less than 5 cm No ultrasound criteria for malignancy The absence of laboratory criteria for malignancy Have informed consent to enter the study Maximum 45 years

Exclusion criteria

Exclusion criteria: Hormonal treatment includes Contraceptive 3 months before entering the study Cabergolin sensitivity

Design outcomes

Primary

Measure	Time frame
Primary outcome: 25% reduction in endometrium size. Timepoint: Treatment is done for 12 weeks for intervention and control groups. Method of measurement: The results of ultrasound.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAbolfazl Mehdizadeh-Kashi

Iran University of Medical Sciences

s.rokhgireh@gmail.com+98 66509283

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026